We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OKLO's Isotope Push Could Support Long-Term Growth Opportunity
Read MoreHide Full Article
Key Takeaways
OKLO is building an isotopes business to target fragile supply for medicine, industry, and security.
OKLO plans an integrated model to turn nuclear waste into usable isotopes via waste partnerships.
OKLO expects early output from Idaho Radiochemistry Lab as it scales toward commercial rollout.
Oklo Inc.’s (OKLO - Free Report) isotopes business is emerging as a key pillar within its broader nuclear platform, targeting a critical gap in the supply of high-value radioactive materials. These isotopes are essential for applications ranging from cancer treatment and diagnostic imaging to advanced manufacturing and national security, making this segment strategically important. Today, global supply remains fragile, with production concentrated in a few aging reactors outside the United States. As many of these facilities approach retirement, supply risks are rising even as demand accelerates, particularly in nuclear medicine, where millions of procedures depend on timely isotope availability.
To address this imbalance, OKLO is developing an integrated production model that converts nuclear waste into valuable isotopes. By sourcing material through both domestic and international waste partnerships, OKLO is building a system that can receive waste, process it, and deliver usable isotopes efficiently. This approach is designed to strengthen supply reliability while reducing reliance on foreign sources. Early-stage facilities, such as the Idaho Radiochemistry Laboratory, are expected to generate initial output while helping validate production methods and bridge the transition from pilot-scale operations to commercial deployment.
A phased infrastructure rollout underpins this strategy, with multiple facilities planned to scale production over time. The Groves Isotope Test Reactor in Texas is intended to demonstrate reactor performance and validate isotope production pathways before larger commercial facilities are developed. Over time, additional assets such as multi-reactor isotope foundries and fuel recycling centers are expected to expand output and integrate isotope production into the broader nuclear fuel cycle. This layered approach reflects OKLO’s effort to establish a stable, domestic supply chain capable of supporting growing demand across health care, industry and research.
While OKLO is pursuing a vertically integrated approach, it is not the only company positioned to benefit from rising isotope demand. A handful of other players are also building strong positions in this market through established production capabilities, government partnerships and broad distribution networks.
Other Isotope Players Worth Watching
BWX Technologies (BWXT - Free Report) is a key U.S. player in nuclear materials and isotope production, with growing importance in medical isotopes like Mo-99 and actinium-225. BWX Technologies benefits from strong government partnerships and a secure domestic supply chain. The company is also expanding into advanced reactor technologies, which could support future isotope production. Overall, BWX Technologies is positioning itself as a reliable and strategic supplier in a market facing increasing isotope demand.
Meanwhile, Sotera Health (SHC - Free Report) , through its Nordion subsidiary, is a major global supplier of cobalt-60 used in cancer treatment and medical sterilization. Sotera Health plays a critical role in ensuring consistent isotope availability for healthcare systems worldwide. Sotera Health benefits from an established commercial distribution network and long-term customer relationships. With rising global demand and supply constraints, Sotera Health is well positioned to remain a key player in the isotope supply chain.
The Zacks Rundown on OKLO
Shares of Oklo have surged some 94% over the past year, breezing past the industry's growth.
Image Source: Zacks Investment Research
OKLO currently has an average brokerage recommendation (ABR) of 1.90 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 20 brokerage firms.
Image Source: Zacks Investment Research
See how the Zacks Consensus Estimate for OKLO’s earnings has been revised over the past 90 days.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
OKLO's Isotope Push Could Support Long-Term Growth Opportunity
Key Takeaways
Oklo Inc.’s (OKLO - Free Report) isotopes business is emerging as a key pillar within its broader nuclear platform, targeting a critical gap in the supply of high-value radioactive materials. These isotopes are essential for applications ranging from cancer treatment and diagnostic imaging to advanced manufacturing and national security, making this segment strategically important. Today, global supply remains fragile, with production concentrated in a few aging reactors outside the United States. As many of these facilities approach retirement, supply risks are rising even as demand accelerates, particularly in nuclear medicine, where millions of procedures depend on timely isotope availability.
To address this imbalance, OKLO is developing an integrated production model that converts nuclear waste into valuable isotopes. By sourcing material through both domestic and international waste partnerships, OKLO is building a system that can receive waste, process it, and deliver usable isotopes efficiently. This approach is designed to strengthen supply reliability while reducing reliance on foreign sources. Early-stage facilities, such as the Idaho Radiochemistry Laboratory, are expected to generate initial output while helping validate production methods and bridge the transition from pilot-scale operations to commercial deployment.
A phased infrastructure rollout underpins this strategy, with multiple facilities planned to scale production over time. The Groves Isotope Test Reactor in Texas is intended to demonstrate reactor performance and validate isotope production pathways before larger commercial facilities are developed. Over time, additional assets such as multi-reactor isotope foundries and fuel recycling centers are expected to expand output and integrate isotope production into the broader nuclear fuel cycle. This layered approach reflects OKLO’s effort to establish a stable, domestic supply chain capable of supporting growing demand across health care, industry and research.
While OKLO is pursuing a vertically integrated approach, it is not the only company positioned to benefit from rising isotope demand. A handful of other players are also building strong positions in this market through established production capabilities, government partnerships and broad distribution networks.
Other Isotope Players Worth Watching
BWX Technologies (BWXT - Free Report) is a key U.S. player in nuclear materials and isotope production, with growing importance in medical isotopes like Mo-99 and actinium-225. BWX Technologies benefits from strong government partnerships and a secure domestic supply chain. The company is also expanding into advanced reactor technologies, which could support future isotope production. Overall, BWX Technologies is positioning itself as a reliable and strategic supplier in a market facing increasing isotope demand.
Meanwhile, Sotera Health (SHC - Free Report) , through its Nordion subsidiary, is a major global supplier of cobalt-60 used in cancer treatment and medical sterilization. Sotera Health plays a critical role in ensuring consistent isotope availability for healthcare systems worldwide. Sotera Health benefits from an established commercial distribution network and long-term customer relationships. With rising global demand and supply constraints, Sotera Health is well positioned to remain a key player in the isotope supply chain.
The Zacks Rundown on OKLO
Shares of Oklo have surged some 94% over the past year, breezing past the industry's growth.
OKLO currently has an average brokerage recommendation (ABR) of 1.90 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 20 brokerage firms.
See how the Zacks Consensus Estimate for OKLO’s earnings has been revised over the past 90 days.
The company currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.